Search

Veracyte Inc

Avatud

SektorTervishoid

41.21 -3.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

40.98

Max

43.6

Põhinäitajad

By Trading Economics

Sissetulek

-3.2M

25M

Müük

11M

150M

P/E

Sektori keskmine

33.774

57.002

Aktsiakasum

0.37

Kasumimarginaal

16.957

Töötajad

755

EBITDA

-11M

24M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+35.56% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-718M

3.7B

Eelmine avamishind

44.25

Eelmine sulgemishind

41.21

Uudiste sentiment

By Acuity

50%

50%

171 / 340 Pingereas Healthcare

Veracyte Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. aug 2026, 19:51 UTC

Veracyte Inc shares are lower today, breaking a trend of higher closes. No specific news was identified for this decline amid notable market volume.

12. aug 2026, 20:01 UTC

Veracyte Inc shares are lower today, following a broader market decline. The stock remains significantly below its 20-day moving average.

11. aug 2026, 19:26 UTC

News

Veracyte Inc reported second-quarter revenue of $150.32 million and raised its 2026 outlook to $590 million to $596 million, boosting shares higher.

10. aug 2026, 19:36 UTC

News

Veracyte Inc shares declined Monday, trading lower since Friday's close amid broader market volatility and rising oil prices affecting inflation expectations.

7. aug 2026, 19:26 UTC

Correlated Moves

Veracyte Inc shares are higher, supported by a rise in the ARK Genomic Revolution ETF and broader small-cap strength from the Russell 2000 Index.

6. aug 2026, 19:26 UTC

Veracyte Inc shares are higher today, despite earlier losses. No specific news was identified to explain the price movement during the session.

5. aug 2026, 19:32 UTC

Veracyte Inc's shares are lower, reflecting broader market sentiment amid recent crude oil price declines. Trading volume is unusually high today.

4. aug 2026, 19:36 UTC

News
Correlated Moves

Veracyte shares are rising as Piper Sandler and Stephens maintain Overweight ratings, despite lowering price targets to $54 and $55, respectively.

3. aug 2026, 20:06 UTC

Veracyte Inc's shares are lower today, diverging from broader market gains amid high trading volume. No specific news was identified to explain the decline.

1. aug 2026, 00:01 UTC

Veracyte Inc is trading lower in after-market hours, reflecting broader market declines. Shares remain near the lower end of their one-month range.

31. juuli 2026, 20:02 UTC

News
Social Media

Veracyte Inc shares are lower despite positive analyst outlooks and target increases from Freedom and Needham following a recent earnings report that exceeded expectations.

30. juuli 2026, 23:21 UTC

News
Social Media

Veracyte shares fell in after-market trading despite reporting second-quarter revenue of $150.3 million and adjusted EPS of $0.54, exceeding expectations.

29. juuli 2026, 19:47 UTC

Macro Event

Veracyte Inc's shares are advancing as the Federal Reserve maintains interest rates. The decision aligns with market expectations amid ongoing economic expansion.

28. juuli 2026, 15:22 UTC

Veracyte Inc. shares are higher today, supported by broader strength in biotechnology stocks. No specific news was identified to explain the price movement.

27. juuli 2026, 20:14 UTC

Veracyte Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment may be affected by declining crude oil prices.

24. juuli 2026, 22:16 UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

22. juuli 2026, 20:13 UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21. juuli 2026, 17:16 UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20. juuli 2026, 20:01 UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Võrdlus sarnastega

Hinnamuutus

Veracyte Inc Prognoos

Hinnasiht

By TipRanks

35.56% tõus

12 kuu keskmine prognoos

Keskmine 57.75 USD  35.56%

Kõrge 70 USD

Madal 44 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Veracyte Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

8

Osta

1

Hoia

1

Müü

Sentiment

By Acuity

171 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
help-icon Live chat